RNA-targeted therapeutics for lipid disorders

Area of Science:

• Cardiovascular Medicine
• RNA Therapeutics
• Lipid Metabolism

Background:

• Significant unmet needs persist in managing lipid disorders, including elevated LDL-cholesterol, remnant-cholesterol, triglycerides, and lipoprotein(a) [Lp(a)].
• Current small molecule and antibody therapies are insufficient for many patients.
• RNA-directed therapeutics represent a novel approach to reduce atherogenic lipoproteins by targeting mRNA to inhibit protein translation.

Purpose of the Study:

• To review recent advancements in RNA-directed therapeutics for lipid disorders.
• To highlight the potential of these novel therapies in addressing unmet clinical needs.

Main Methods:

• Review of current RNA-directed therapeutic strategies, including small interfering RNA (siRNA) and antisense oligonucleotides (ASO).
• Focus on agents targeting key proteins involved in lipid metabolism, such as PCSK9, apoC-III, ANGPTL3, and LPA.
• Examination of therapies in clinical trials (Phase 1-3).

Main Results:

• siRNA targeting PCSK9 reduces LDL-C.
• ASOs targeting apoC-III and ANGPTL3 reduce triglycerides and LDL-C.
• ASOs targeting LPA reduce Lp(a).
• These RNA-based therapies demonstrate distinct differences in chemistry, delivery, and mechanism of action.

Conclusions:

• Novel RNA therapeutics are emerging as potent and specific treatments for reducing atherogenic lipoproteins.
• These therapies promise to expand treatment options, enabling clinicians to manage lipid disorders more effectively.
• Successful implementation of RNA therapeutics can significantly reduce cardiovascular disease risk.